Ankylosing spondylitis market seen reaching $9.42 billion by 2030

The Business Research Company says the global ankylosing spondylitis market will grow from $6.85 billion in 2026 to $9.42 billion by 2030, driven by biologics, biosimilars and more personalized care. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Ankylosing spondylitis is a chronic inflammatory disease that affects the spine and sacroiliac joints and can limit mobility over time. - Faster diagnosis, broader treatment access and new biologic therapies are reshaping how patients are managed. - The market outlook points to more demand for long-term autoimmune care and advanced treatment options.

What happened: - The Business Research Company released its "Ankylosing Spondylitis Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report says the market was worth $6.34 billion in 2025 and is projected to reach $6.85 billion in 2026. - The report projects the market will grow to $9.42 billion by 2030 at a CAGR of 8.3%. - A free sample of the report is available here. - The full report is available here.

The details: - Historical growth has been supported by wider use of NSAIDs and DMARDs, expanded access to specialist rheumatology care, more hospital-based treatment options and greater use of imaging for disease monitoring. - Future growth is expected to come from rising use of biologic drugs and biosimilars, stronger demand for personalized medicine and more investment in autoimmune disease research. - The report highlights growing adoption of biologic therapies, increased use of targeted DMARDs, earlier diagnosis, personalized treatment strategies and better integration of physical therapy programs. - Ankylosing spondylitis primarily targets the spine and pelvis and causes inflammation, pain, stiffness and progressive loss of spinal mobility. - The report frames rising autoimmune disease prevalence as a key demand driver. - The report cites Canada’s IBD Clinical and Research Centre, which said in September 2023 that more than 320,000 Canadians live with inflammatory bowel disease, with prevalence at 825 per 100,000 in 2023. - The same report projected IBD cases in Canada will rise 2.44% a year, reaching about 470,000 people, or 1.1% of the population, by 2035.

Between the lines: - The market story is shifting from basic symptom management toward longer-term, more tailored disease control. - Biologics and biosimilars are likely to matter because they can expand treatment options for patients who need more than standard anti-inflammatory therapy. - The link to autoimmune conditions such as IBD suggests ankylosing spondylitis demand may rise alongside broader immune-disease diagnosis and treatment trends. - North America held the largest market share in 2025, but Asia-Pacific is forecast to be the fastest-growing region.

What's next: - The report expects continued growth through 2030 as treatment innovation and autoimmune disease awareness expand. - Regional momentum is likely to remain strongest in Asia-Pacific while North America keeps the largest share for now. - The report’s broader regional coverage includes South East Asia, Western and Eastern Europe, South America, the Middle East and Africa. - The Business Research Company also says its 2026 reports include TAM analysis, company scoring matrices, forecasting dashboards, market hotspot infographics and trend analysis.

The bottom line: - The ankylosing spondylitis market is on track for steady expansion, with biologics, biosimilars and more personalized treatment driving the next phase of growth.